Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Amplifications and deletions in clinical ovarian cancer detected by Comparative Genomic Hybridization (CGH)

Conference · · Cytometry (Baltimore); (United States)
OSTI ID:6572941
; ; ; ; ; ;  [1];  [2]
  1. Univ. of California, San Francisco (United States)
  2. Yale Univ., New Haven, CT (United States)

CGH is a new powerful method for surveying the whole genome for DNA sequence copy number changes in a single hybridization. The method is based on the competition between biotinylated total tumor DNA and a digoxigenin-labeled normal genomic reference DNA during hybridization to normal metaphase chromosomes. After immunofluorescent staining with avidin-FITC and antidigoxigenin Rhodamine, variation of DNA sequence copy numbers in the tumor are detected as variations in the ratios of green and red fluorescence along each chromosome. The authors applied CGH analysis to DNA extracted from surgically removed ovarian cancer specimens (27 cases). Seven amplified regions were identified by CGH analysis. Three loci, 1p32-p34 (most likely, MYCL), 8q23-q24 (MYC), 12q12 (KRAS2), were known to be amplified in solid tumors and four other loci (3q26, 6p22, 9q31-q33, 17q22) were previously unknown to be amplified. Many regions indicating physical deletions were also identified by the analysis. Chromosomal regions showing frequent deletion were 1p, 3p, 17p, 17q, 19p, 19q and Xp. There were also significant similarities of the regions with amplifications and deletions between bilateral ovarian tumors or among several different tumors form the same ovarian cancer cases, suggesting that the genetic changes observed might be relatively early events during the progression of ovarian cancer.

OSTI ID:
6572941
Report Number(s):
CONF-9303114--
Journal Information:
Cytometry (Baltimore); (United States), Journal Name: Cytometry (Baltimore); (United States) Vol. 6; ISSN CYTODQ; ISSN 0196-4763
Country of Publication:
United States
Language:
English